Back |
home / stock / tsha / tsha message board
Subject | By | Source | When |
---|---|---|---|
Guess the float just got locked and MMs | KOmani | investorshub | 10/25/2022 3:57:28 PM |
TSHA is the top % Gainer in the | MiamiGent | investorshub | 10/25/2022 3:33:19 PM |
Yea! I agree with you 100% | subslover | investorshub | 10/25/2022 1:06:05 PM |
Yea! I agree with you 100% | subslover | investorshub | 10/25/2022 1:06:04 PM |
Just as I post this it seems like | KOmani | investorshub | 10/25/2022 12:13:44 PM |
Doesn't this imply $7ish per share value? | KOmani | investorshub | 10/25/2022 12:09:56 PM |
Astellas and Taysha Gene Therapies Announce Strategic Investment | subslover | investorshub | 10/25/2022 9:22:27 AM |
News, Short Squeeze, Breakout and More Instantly...
Taysha Gene Therapies Inc. Company Name:
TSHA Stock Symbol:
NASDAQ Market:
Taysha Gene Therapies Inc. Website:
2024-06-26 17:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for TSHA on June 26, 2024 04:10PM ET. TSHA was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 1 - Hol...
DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an ...
DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commen...